Physician

Saleem Sajid, M.D.

According to 2025 Medicare claims, Saleem Sajid, M.D. (NPI: 1366424293) practices rheumatology in the Elizabethtown, KY market, with the plurality of this provider's patient population coming from Hardin, KY. This provider's primary affiliated billing organization is LAKE CUMBERLAND RHEUMATOLOGY, PLLC (NPI: 1619117058; TIN: 264240766) and primary practice location at 42701-2988.

Sajid's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 358 traditional Medicare patients, billed 12,614 HCPCS/CPT codes, and received $302,278 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 2,247 prescription claims across 347 beneficiaries totaling $4,073,357 in drug costs, led by Enbrel Sureclick (Etanercept). 2019 DME data shows 12 claims. Open Payments data shows 148 records totaling $5,261. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $171,662 to $302,278. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,035,260 to $4,073,357. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	446	3,109	$171,662
2016	443	2,860	$162,123
2017	447	4,974	$221,288
2018	481	12,485	$460,729
2019	517	18,000	$568,853
2020	432	20,693	$557,843
2021	395	19,714	$484,334
2022	354	14,819	$345,409
2023	321	14,424	$318,711
2024	358	12,614	$302,278

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	299	3,028	$1,035,260
2016	297	2,707	$1,124,774
2017	264	2,477	$1,592,296
2018	286	2,438	$1,665,483
2019	323	2,625	$2,374,948
2020	351	2,988	$2,796,607
2021	329	2,969	$3,747,411
2022	331	2,689	$3,797,049
2023	330	2,571	$4,429,200
2024	347	2,247	$4,073,357

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	19	$4,255
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	12	$185
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	126	126	$111
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	263	756	$83
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	65	113	$61
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	189	315	$11
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	83	332	$1

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Sureclick	Etanercept	174	4,884	$1,274,018
Humira(Cf) Pen	Adalimumab	120	3,447	$869,191
Xeljanz Xr	Tofacitinib Citrate	62	1,890	$372,403
Rinvoq	Upadacitinib	55	1,710	$355,589
Enbrel Mini	Etanercept	30	854	$231,734

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	148	$5,261	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Saleem Sajid, M.D.?

Tedicare shows public-source Medicare data for Saleem Sajid, M.D. (NPI 1366424293), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Saleem Sajid, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Saleem Sajid, M.D.?

Saleem Sajid, M.D. is linked to LAKE CUMBERLAND RHEUMATOLOGY, PLLC (billing NPI 1619117058) in the available physician profile data.

Does Saleem Sajid, M.D. have Open Payments data?

Saleem Sajid, M.D. has 148 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.